Integrum AB Series B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more
Integrum AB Series B (INTEG-B) - Net Assets
Latest net assets as of September 2025: Skr156.95 Million SEK
Based on the latest financial reports, Integrum AB Series B (INTEG-B) has net assets worth Skr156.95 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr179.05 Million) and total liabilities (Skr22.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr156.95 Million |
| % of Total Assets | 87.66% |
| Annual Growth Rate | 44.83% |
| 5-Year Change | 632.17% |
| 10-Year Change | 15571.81% |
| Growth Volatility | 272.74 |
Integrum AB Series B - Net Assets Trend (2013–2024)
This chart illustrates how Integrum AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Integrum AB Series B (2013–2024)
The table below shows the annual net assets of Integrum AB Series B from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr177.88 Million | +24.57% |
| 2023-12-31 | Skr142.79 Million | -0.52% |
| 2022-12-31 | Skr143.53 Million | -10.15% |
| 2021-12-31 | Skr159.74 Million | +557.52% |
| 2020-12-31 | Skr24.29 Million | +2.39% |
| 2019-12-31 | Skr23.73 Million | +47.82% |
| 2018-12-31 | Skr16.05 Million | -10.84% |
| 2017-12-31 | Skr18.00 Million | +70.90% |
| 2016-12-31 | Skr10.53 Million | +828.13% |
| 2015-12-31 | Skr1.14 Million | +0.09% |
| 2014-12-31 | Skr1.13 Million | -62.51% |
| 2013-12-31 | Skr3.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Integrum AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2367.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.49 Million | 0.84% |
| Other Components | Skr242.69 Million | 136.44% |
| Total Equity | Skr177.88 Million | 100.00% |
Integrum AB Series B Competitors by Market Cap
The table below lists competitors of Integrum AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RP Optical Lab Ltd
TA:RPOL
|
$10.18 Million |
|
Profoto Holding AB
ST:PRFO
|
$10.19 Million |
|
Advance Metals Ltd
AU:AVM
|
$10.19 Million |
|
CRTUF
PINK:CRTUF
|
$10.19 Million |
|
Biomind Labs Inc.
PINK:BMNDF
|
$10.18 Million |
|
ReVolve Renewable Power Corp.
OTCQB:REVVF
|
$10.18 Million |
|
Burgundy Diamond Mines Ltd
AU:BDM
|
$10.17 Million |
|
Iris Business Services Limited
NSE:IRIS
|
$10.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Integrum AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 142,786,269 to 177,875,000, a change of 35,088,731 (24.6%).
- Net loss of 30,852,000 reduced equity.
- Share repurchases of 74,866,000 reduced equity.
- New share issuances of 74,866,000 increased equity.
- Other comprehensive income increased equity by 12,294,053.
- Other factors increased equity by 53,646,678.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-30.85 Million | -17.34% |
| Share Repurchases | Skr74.87 Million | -42.09% |
| Share Issuances | Skr74.87 Million | +42.09% |
| Other Comprehensive Income | Skr12.29 Million | +6.91% |
| Other Changes | Skr53.65 Million | +30.16% |
| Total Change | Skr- | 24.57% |
Book Value vs Market Value Analysis
This analysis compares Integrum AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 26.24x to 0.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.30 | Skr8.00 | x |
| 2014-12-31 | Skr0.11 | Skr8.00 | x |
| 2015-12-31 | Skr0.11 | Skr8.00 | x |
| 2016-12-31 | Skr1.18 | Skr8.00 | x |
| 2017-12-31 | Skr1.81 | Skr8.00 | x |
| 2018-12-31 | Skr1.28 | Skr8.00 | x |
| 2019-12-31 | Skr1.57 | Skr8.00 | x |
| 2020-12-31 | Skr1.53 | Skr8.00 | x |
| 2021-12-31 | Skr8.79 | Skr8.00 | x |
| 2022-12-31 | Skr7.83 | Skr8.00 | x |
| 2023-12-31 | Skr7.41 | Skr8.00 | x |
| 2024-12-31 | Skr8.34 | Skr8.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Integrum AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.87%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.14x
- Recent ROE (-17.34%) is above the historical average (-28.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 56.82% | 9.05% | 2.20x | 2.86x | Skr1.42 Million |
| 2014 | 0.02% | 0.00% | 2.31x | 5.66x | Skr-113.22K |
| 2015 | 0.02% | 0.00% | 1.21x | 8.96x | Skr-113.30K |
| 2016 | -54.54% | -32.26% | 0.90x | 1.88x | Skr-6.80 Million |
| 2017 | -101.97% | -120.99% | 0.58x | 1.47x | Skr-20.16 Million |
| 2018 | -153.16% | -109.50% | 0.90x | 1.55x | Skr-26.19 Million |
| 2019 | -66.11% | -58.65% | 0.83x | 1.36x | Skr-18.06 Million |
| 2020 | -8.81% | -4.97% | 1.16x | 1.53x | Skr-4.57 Million |
| 2021 | 13.32% | 38.17% | 0.31x | 1.13x | Skr5.30 Million |
| 2022 | -11.27% | -21.79% | 0.45x | 1.15x | Skr-30.53 Million |
| 2023 | 2.82% | 3.87% | 0.63x | 1.15x | Skr-10.25 Million |
| 2024 | -17.34% | -33.87% | 0.45x | 1.14x | Skr-48.64 Million |
Industry Comparison
This section compares Integrum AB Series B's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Integrum AB Series B (INTEG-B) | Skr156.95 Million | 56.82% | 0.14x | $10.18 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |